Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126584
Title: | Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. |
Author: | Sánchez Ortega, Isabel Parody, Rocío Servitje Bedate, Octavio Muniesa Montserrat, Cristina Arnan, Montserrat Patiño, Beatriz Sureda, Anna Duarte, Rafael |
Keywords: | Ús terapèutic Efectes secundaris dels medicaments Malalties cròniques Therapeutic use Drug side effects Chronic diseases |
Issue Date: | 30-Jun-2016 |
Abstract: | Aim To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). Methods This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment. Results 7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolonged partial response, but died due to an infectious complication while on treatment 5 patients started dasatinib treatment (3 achieved partial responses and discontinued dasatinib, 1 achieved a durable partial response, but died due to a consecutive rapid pulmonary cGVHD progression and 1 with stable disease discontinued treatment due to gastroenteric intolerance). The response rate (partial and/or complete responses) for severe scGVHD was 25% for imatinib and 60% for dasatinib. Conclusion In our series, dasatinib was better tolerated, safer, steroid-sparing, and had a low incidence of infectious complications, which suggests that it may be a more effective therapeutic alternative for patients with refractory scGVHD than imatinib. Treatment of scGVHD with effective antifibrotic drugs such as TKI, which block the kinase fibrotic pathway, may be a safe and effective therapeutic option, but further studies are needed to confirm our findings. |
Note: | Reproducció del document publicat a: https://doi.org/10.3325/cmj.2016.57.247 |
It is part of: | Croatian Medical Journal, 2016, vol. 57, num. 3, p. 247-254 |
URI: | http://hdl.handle.net/2445/126584 |
Related resource: | https://doi.org/10.3325/cmj.2016.57.247 |
ISSN: | 0353-9504 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
667006.pdf | 129.68 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License